Four biotech initial public offerings raised about $1.5 billion in April, the largest month for IPO proceeds in more than five years, according to Renaissance Capital. The new flotations included Hemab Therapeutics and Seaport Therapeutics, both described as upsized listings. The report highlights the renewed appetite for early- and late-stage biotech stories in the public markets. For companies preparing for financing or strategic partnering, the month’s volume suggests investor demand concentrated around defined clinical pipelines and near-term catalysts. It also comes amid ongoing scrutiny of pricing and commercial potential across oncology and specialty pharma, making IPO execution and post-listing performance an immediate barometer for the sector.